Alnylam Pharmaceuticals is trading on the Nasdaq stock exchange and is receiving analyst coverage and target price reports.
2 reports, 2 independent
Updated Jul 30
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Alnylam Pharmaceuticals is trading on the Nasdaq stock exchange and is receiving analyst coverage and target price reports.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Alnylam lowered its TTR revenue guidance while trading on Nasdaq.1 source
The company is trading on Nasdaq and has received analyst coverage.1 source
Keep exploring
The entities involved
-
Alnylam Pharmaceuticals
biopharmaceutical company
- AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.
- Alnylam Pharmaceuticals, SEC, Truist Financial, and Nasdaq were involved in insider trading disclosures, analyst ratings, and stock trading on June 6, 2026.
-
Nasdaq
American fully electronic stock exchange
Related events
- Alnylam Pharmaceuticals (listed on Nasdaq) and Emergent BioSolutions (listed on NYSE) are two healthcare companies competing for investment.
- Palvella Therapeutics, Inc. stock is trading on the Nasdaq exchange, and the NDA review for its product QTORIN is currently underway.
- BioPharma stock was traded on the NASDAQ stock exchange on July 30, 2026, with its performance tracked by financial blogs.
- American Rebel Holdings, Inc. trades on the Nasdaq stock exchange and receives analyst research notes.
- Jazz Pharmaceuticals and RYTHM are competing in the pharmaceutical market and listed on the Nasdaq stock exchange.